Olleros Santos-Ruiz M, Sádaba M C, Martín-Estal I, Muñoz U, Sebal Neira C, Castilla-Cortázar I
Fundacion de Investigacion HM Hospitales, Madrid, Spain.
Department of Medical Physiology, School of Medicine, Universidad San Pablo-CEU, Madrid, Spain.
Growth Horm IGF Res. 2017 Aug;35:21-32. doi: 10.1016/j.ghir.2017.05.007. Epub 2017 Jun 2.
BACKGROUND & AIMS: We previously described in cirrhosis and aging, both conditions of IGF-1 deficiency, a clear hepatic mitochondrial dysfunction with increased oxidative damage. In both conditions, the hepatic mitochondrial function was improved with low doses of IGF-1. The aim of this work was to explore if the only mere IGF-1 partial deficiency, without any exogenous insult, is responsible for hepatic mitochondrial dysfunction.
Heterozygous (igf1) mice were divided into two groups: untreated and treated mice with low doses of IGF-1. WT group was used as controls. Parameters of hepatic mitochondrial function were determined by flow cytometry, antioxidant enzyme activities were determined by spectrophotometry, and electron chain transport enzyme levels were determined by immunohistochemistry and immunofluorescence analyses. Liver expression of genes coding for proteins involved in mitochondrial protection and apoptosis was studied by microarray analysis and RT-qPCR.
Hz mice showed a significant reduction in hepatic mitochondrial membrane potential (MMP) and ATPase activity, and an increase in intramitochondrial free radical production and proton leak rates, compared to controls. These parameters were normalized by IGF-1 replacement therapy. No significant differences were found between groups in oxygen consumption and antioxidant enzyme activities, except for catalase, whose activity was increased in both Hz groups. Relevant genes coding for proteins involved in mitochondrial protection and survival were altered in Hz group and were reverted to normal in Hz+IGF-1 group.
The mere IGF-1 partial deficiency is per se associated with hepatic mitochondrial dysfunction sensitive to IGF-1 replacement therapy. Results in this work prove that IGF-1 is involved in hepatic mitochondrial protection, because it is able to reduce free radical production, oxidative damage and apoptosis. All these IGF-1 actions are mediated by the modulation of the expression of genes encoding citoprotective and antiapoptotic proteins.
我们之前描述过,在肝硬化和衰老这两种胰岛素样生长因子-1(IGF-1)缺乏的情况下,肝脏线粒体功能明显受损,氧化损伤增加。在这两种情况下,低剂量的IGF-1可改善肝脏线粒体功能。本研究旨在探讨仅IGF-1部分缺乏(无任何外源性损伤)是否会导致肝脏线粒体功能障碍。
将杂合子(igf1)小鼠分为两组:未治疗组和低剂量IGF-1治疗组。野生型(WT)组用作对照。通过流式细胞术测定肝脏线粒体功能参数,用分光光度法测定抗氧化酶活性,通过免疫组织化学和免疫荧光分析测定电子链转运酶水平。通过微阵列分析和逆转录定量聚合酶链反应(RT-qPCR)研究肝脏中参与线粒体保护和凋亡的蛋白质编码基因的表达。
与对照组相比,杂合子小鼠肝脏线粒体膜电位(MMP)和ATP酶活性显著降低,线粒体内自由基产生和质子泄漏率增加。这些参数通过IGF-1替代疗法恢复正常。除过氧化氢酶外,各组之间在氧消耗和抗氧化酶活性方面未发现显著差异,过氧化氢酶活性在两个杂合子组中均增加。杂合子组中参与线粒体保护和存活的蛋白质相关编码基因发生改变,在杂合子+IGF-1组中恢复正常。
仅IGF-1部分缺乏本身与对IGF-1替代疗法敏感的肝脏线粒体功能障碍有关。本研究结果证明IGF-1参与肝脏线粒体保护,因为它能够减少自由基产生、氧化损伤和细胞凋亡。IGF-1的所有这些作用都是通过调节编码细胞保护和抗凋亡蛋白的基因表达来介导的。